Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: committee papers
Table of Contents
01. NICE’s response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD - Roche Products
03. Consultee comments on the ACD - Leukaemia Care
04. Consultee comments on the ACD - Lymphona Association
05. Consultee/Commentator joint comments on the ACD - [National Cancer Research Institute, Royal College of Physicians, Association of Cancer Physicians
![Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: committee papers](/proxy/?sourceUrl=http%3a%2f%2fwww.nice.org.uk%2fimages%2ficons%2fpdf.gif)
|
Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: committee papers
10 March 2015 (898.44 Kb 21 sec) |
This page was last updated: 18 March 2015